Correspondence Letters:

2023

• Gyawali B. Letter to Editor-response: placebo response rates. EClinicalMedicine. 2023 Feb 14;56:101852. PMID: 36851987

2022

• Gyawali B*, Eisenhauer E, Brundage M. Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials-Reply. JAMA Oncol. 2022. PMID: 36006636

• Tannock IF, Booth CM, Gyawali B, Joshua AM. Radiographic progression-free survival in the ACIS trial for prostate cancer. Lancet Oncol. 2022. PMID: 34973231.

2021

• Gupta A^# and Gyawali B*. Digging deeper into cancer-associated financial toxicity in low- and middle-income countries. Cancer Res Stat Treat 2021;4:172-3

2020

• Robinson A, Gyawali B, Booth CM. Risk of COVID-19 in Patients With Cancer. JAMA Oncol. 2020;10.1001/jamaoncol.2020.2586. PMID: 32614417

2018

• Gyawali B* and Goldstein D.Information Transparency in the Drug Approval Process—Reply. JAMA Oncology. PMID: 30193359

2017

• Gyawali B* and Ando Y. FDA Approval Summary: Sonidegib—Letter. Clinical Cancer Research. PMID: 28972085

• Addeo A and Gyawali B. Rushing will not help to choose the best combination. The Lancet Oncology 2017; 18:e186 (PMID: 28368248)

2016

• Gyawali B. Re: Cancer drugs, survival, and ethics. The BMJ.

• Oota A, Gyawali B, Matusoka A and Ando Y. Unconvincing benefit of combination therapy with gefitinib and pemetrexed in advanced NSCLC. Journal of Clinical Oncology (PMID: 27918721)

• Gyawali B*, Oota A, Ando Y. Nivolumab in Nonsquamous Non-small-cell lung cancer. The New England Journal of Medicine. 2016 Feb 4;374(5):493 (PMID: 26840146)

2015

• Gyawali B*, Shimokata T, Ando Y. Discordance between the results and conclusions of ICON7. The Lancet Oncology 2015;16:e478. (PMID: 26433821)

• Honda K, Gyawali B and Ando Y. Survival of patients with metastatic breast cancer with or without locoregional therapy. The Lancet Oncology 16, e586 (2015) (PMID: 26678206).

• Gyawali B*, Shimokata T, Honda K, Ando Y. Flaws in the trial design of IFCT-0802. Annals of Oncology 2015;26:2003. (PMID: 26113649)

• Gyawali B*, Tsukuura H, Honda K, Shimokata T, Ando Y. Some questions on the randomized controlled trial of communication skills training for oncologists. Journal of clinical oncology: 2015;33:222. ( PMID: 25452450)

2014

• Gyawali B*, Poudyal B, Shimokata T, Ando Y. Cancer care and research in India: what does it mean to Nepal? The Lancet Oncology 2014;15:e299-e300. (PMID:24988923)